Novavax Inc. [NASDAQ: NVAX] price surged by 6.41 percent to reach at $7.06. The company report on October 13, 2020 that Novavax Appoints Leadership Team to Advance NanoFlu through Regulatory Licensure.
Team will focus on global NanoFlu licensure and evaluation of post-pandemic influenza/COVID-19 combination vaccine with NVX-CoV2373 .
Russell (Rip) Wilson promoted to Executive Vice President and NanoFlu General Manager .
A sum of 4414160 shares traded at recent session while its average daily volume was at 6.63M shares. Novavax Inc. shares reached a high of $120.6499 and dropped to a low of $110.95 until finishing in the latest session at $117.28.
The average equity rating for NVAX stock is currently 2.70, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Novavax Inc. [NVAX]:
H.C. Wainwright have made an estimate for Novavax Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 06, 2020. The new note on the price target was released on August 05, 2020, representing the official price target for Novavax Inc. stock. Previously, the target price had yet another raise to $105, while Ladenburg Thalmann analysts kept a Sell rating on NVAX stock. On July 16, 2020, analysts increased their price target for NVAX shares from 101 to 132.
The Average True Range (ATR) for Novavax Inc. is set at 8.33, with the Price to Sales ratio for NVAX stock in the period of the last 12 months amounting to 142.91. The Price to Book ratio for the last quarter was 37.23, with the Price to Cash per share for the same quarter was set at 8.21. Price to Free Cash Flow for NVAX in the course of the last twelve months was 224.19 with Quick ratio for the last quarter at 3.00.
NVAX Stock Performance Analysis:
Novavax Inc. [NVAX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 9.19. With this latest performance, NVAX shares gained by 10.85% in over the last four-week period, additionally plugging by 569.02% over the last 6 months – not to mention a rise of 2400.64% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVAX stock in for the last two-week period is set at 53.89, with the RSI for the last a single of trading hit 62.96, and the three-weeks RSI is set at 53.45 for Novavax Inc. [NVAX]. The present Moving Average for the last 50 days of trading for this stock 119.68, while it was recorded at 111.95 for the last single week of trading, and 58.62 for the last 200 days.
Insight into Novavax Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Novavax Inc. [NVAX] shares currently have an operating margin of -694.44. Novavax Inc.’s Net Margin is presently recorded at -711.04.
Return on Total Capital for NVAX is now -87.24, given the latest momentum, and Return on Invested Capital for the company is -89.70. Additionally, NVAX Total Debt to Total Capital is recorded at 227.53, with Total Debt to Total Assets ending up at 191.88.
Reflecting on the efficiency of the workforce at the company, Novavax Inc. [NVAX] managed to generate an average of -$804,206 per employee. Receivables Turnover for the company is 4.98 with a Total Asset Turnover recorded at a value of 0.10.Novavax Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.00 and a Current Ratio set at 3.00.
NVAX Stock EPS
With the latest financial reports released by the company, Novavax Inc. posted -0.74/share EPS, while the average EPS was predicted by analysts to be reported at -0.98/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 24.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVAX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novavax Inc. go to 0.00%.
Novavax Inc. [NVAX] Insider Position Details
There are presently around $3,731 million, or 53.40% of NVAX stock, in the hands of institutional investors. The top three institutional holders of NVAX stocks are: RA CAPITAL MANAGEMENT, L.P. with ownership of 4,758,833, which is approximately New of the company’s market cap and around 0.20% of the total institutional ownership; VANGUARD GROUP INC, holding 4,637,637 shares of the stock with an approximate value of $543.9 million in NVAX stocks shares; and BLACKROCK INC., currently with $538.65 million in NVAX stock with ownership of nearly 66.93% of the company’s market capitalization.
Positions in Novavax Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 169 institutional holders increased their position in Novavax Inc. [NASDAQ:NVAX] by around 20,414,899 shares. Additionally, 49 investors decreased positions by around 1,803,010 shares, while 14 investors held positions by with 9,591,062 shares. The mentioned changes placed institutional holdings at 31,808,971 shares, according to the latest SEC report filing. NVAX stock had 114 new institutional investments in for a total of 8,516,985 shares, while 19 institutional investors sold positions of 153,439 shares during the same period.